Role of CD146 (MCAM) in Physiological and Pathological Angiogenesis—Contribution of New Antibodies for Therapy

Archive ouverte

Joshkon, Ahmad | Heim, Xavier | Dubrou, Cléa | Bachelier, Richard | Traboulsi, Wael | Stalin, Jimmy | Fayyad-Kazan, Hussein | Badran, Bassam | Foucault-Bertaud, Alexandrine | Leroyer, Aurelie | Bardin, Nathalie | Blot-Chabaud, Marcel

Edité par CCSD ; MDPI -

International audience. The fundamental role of cell adhesion molecules in mediating various biological processes as angiogenesis has been well-documented. CD146, an adhesion molecule of the immunoglobulin superfamily, and its soluble form, constitute major players in both physiological and pathological angiogenesis. A growing body of evidence shows soluble CD146 to be significantly elevated in the serum or interstitial fluid of patients with pathologies related to deregulated angiogenesis, as autoimmune diseases, obstetric and ocular pathologies, and cancers. To block the undesirable effects of this molecule, therapeutic antibodies have been developed. Herein, we review the multifaceted functions of CD146 in physiological and pathological angiogenesis and summarize the interest of using monoclonal antibodies for therapeutic purposes.

Suggestions

Du même auteur

Role of CD146 (MCAM) in Physiological and Pathological Angiogenesis—Contribution of New Antibodies for Therapy

Archive ouverte | Joshkon, Ahmad | CCSD

International audience. The fundamental role of cell adhesion molecules in mediating various biological processes as angiogenesis has been well-documented. CD146, an adhesion molecule of the immunoglobulin superfami...

CD146/sCD146 in the Pathogenesis and Monitoring of Angiogenic and Inflammatory Diseases

Archive ouverte | Heim, Xavier | CCSD

International audience. CD146 is a cell adhesion molecule expressed on endothelial cells, as well as on other cells such as mesenchymal stem cells and Th17 lymphocytes. This protein also exists in a soluble form, wh...

Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma

Archive ouverte | Joshkon, Ahmad | CCSD

International audience. Rationale Glioblastoma multiforme (GBM) is a primary brain tumor with poor prognosis. The U.S. food and drug administration approved the use of the anti-VEGF antibody bevacizumab in recurrent...

Chargement des enrichissements...